Back to News
Market Impact: 0.22
Ironwood: Medicare Is Not The Problem I Thought It Was
Source: seekingalpha.com
Analyst InsightsHealthcare & BiotechCompany FundamentalsConsumer Demand & Retail
Ironwood Pharmaceuticals is rated Buy with a $5.25 fair-value estimate. LINZESS generated $143.74 per 30 capsules, near Medicare's projected 2027 price of $136. Sales rose 44%, but the increase was primarily price-driven, while underlying demand grew only 4% to 5%, limiting the strength of the operating-growth signal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
IRWD0.32
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Federal Reserve is likely to hold interest rates steady in October. Here's what that means for consumers
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean